HDM201

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

Metastatic Colorectal CancerMyelodysplastic SyndromeSoft Tissue SarcomaLiposarcomaMalignant Solid TumorAdvanced Soft-Tissue Sarcoma

698 competitors in Metastatic Colorectal Cancer

#DrugCompanyPhaseTrials

1

Xeloda

EEngelhard Arzneimittel GmbH & Co.KG

Phase 3

942

Erbitux

IImclone

Phase 3

1133

Braftovi

Pfizer

Phase 3

114

Sutent

Pfizer

Phase 3

35

Innohep

Alnylam Pharmaceuticals

Phase 3

16

Lenvima

Eisai

Phase 3

17

Celebrex

PPhiladelphia Eye Associates

Phase 3

98

Cosela

PPharmacosmos A/S

Phase 3

19

Xeloda

Roche

Phase 3

310

XL092

Roche

Phase 3

1Show 21 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Metastatic Colorectal Cancer1 trial

Trametinib + HDM201 in CRC Patients With RAS/RAF Mutant and TP53 Wild-type Advanced/Metastatic Colorectal Cancer Mutant and TP53 Wild-type

Completed·CCentre Leon Berard·Phase 1·NCT03714958·12 enrolled

Relapsed/Refractory AML1 trial

HDM201 and Midostaurin (HDMM) in Relapsed/Refractory AML With FLT3mut and TP53wt.

Terminated·IInsel Gruppe AG, University Hospital Bern·Phase 1·NCT04496999·2 enrolled

Newly Diagnosed1 trial

HDM201 Added to CT in R/R or Newly Diagnosed AML

Withdrawn·Novartis·Phase 1/2·NCT03760445

Myelodysplastic Syndrome1 trial

HDM201 in Combination With MBG453 or Venetoclax in Patients With Acute Myeloid Leukemia (AML) or High-risk Myelodysplastic Syndrome (MDS)

Terminated·Novartis·Phase 1·NCT03940352·52 enrolled

Advanced1 trial

Study to Determine and Evaluate a Safe and Tolerated Dose of HDM201 in Patients With Selected Advanced Tumors That Are TP53wt

Completed·Novartis·Phase 1·NCT02143635·208 enrolled

4 more indications

Liposarcoma1 trial

Study of Safety and Efficacy of HDM201 in Combination With LEE011 in Patients With Liposarcoma

Completed·Novartis·Phase 1·NCT02343172·74 enrolled

Malignant Solid Tumor1 trial

MegaMOST - A Multicenter, Open-label, Biology Driven, Phase II Study Evaluating the Activity of Anti-cancer Treatments Targeting Tumor Molecular Alterations /Characteristics in Advanced / Metastatic Tumors.

Recruiting·CCentre Leon Berard·Phase 2·NCT04116541·455 enrolled

Advanced Soft-tissue Sarcoma1 trial

A Multicenter, Phase I/II Study Evaluating the Clinical Impact of HDM201 + Pazopanib in Patients With P53 Wild-type Advanced/ Metastatic Soft Tissue Sarcomas (AMPHISARC)

Active, not recruiting·CCentre Leon Berard·Preclinical·NCT05180695·47 enrolled

Unspecified1 trial

A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat

Completed·Novartis·Phase 1·NCT02890069·298 enrolled

Details

Drug Info

Related News